foscarnet / Generic mfg. - LARVOL DELTA

TRIAL IN PROGRESS: A PHASE 2, SINGLE-ARM, MULTICENTER STUDY OF MARIBAVIR FOR CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH LYMPHOID MALIGNANCIES UNDERGOING BISPECIFIC ANTIBODIES (MALMBA) (EBMT 2026) - P2 | "Unlike conventional CMV agents such as ganciclovir, cidofovir, and foscarnet—often restricted by myelosuppression or renal toxicity—maribavir provides robust antiviral activity without hematologic toxicity, supporting its use in immunocompromised populations. No data are available at this stage as the trial is ongoing."

Clinical • P2 data • B Cell Lymphoma • Cytomegalovirus Infection • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • CD8 • IFNG

LETERMOVIR USE IN PEDIATRIC HSCT PATIENTS UNDER 12 YEARS OLD: UPDATED DATA FROM A RETROSPECTIVE MULTICENTER STUDY OF THE PDWP AND IEWP OF THE EBMT (EBMT 2026) - "Conditioning regimens included treosulfan-based (44.5%), TBI-based (32.2%), busulfan-based (15.1%), and other (8.2%). In-vivo T-cell depletion (TCD) was used in 34.2% of patients (ATG 27.4%, Campath 6.8%), and ex-vivo TCD in 11.6%.Table 1: Patient and transplant characteristics With a median follow-up of 1 year (95% CI: 0.9–1.1), the 1-year cumulative incidence of CMV reactivation was 23.8% (95% CI: 16–30) overall, 21.4% (95% CI: 13.6–29.2) during primary prophylaxis, and 32.6% (95% CI: 13.1–45) during secondary prophylaxis (Figure 1)...Among patients with CMV reactivation, one death was attributed to relapsed disease.Letermovir was well tolerated with only two patients experiencing mild gastrointestinal toxicity, and no additional significant adverse events reported.CMV reactivations were managed using standard antiviral strategies, including valganciclovir (n=10), ganciclovir (n=8), foscarnet (n=7), and cidofovir (n=1) or continued letermovir alone (n=8)... In this..."

Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hepatology • Immunology • Infectious Disease • Pediatrics

MARIBAVIR FOR CYTOMEGALOVIRUS INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL-WORLD, MULTICENTER, COMPARATIVE COHORT STUDY (EBMT 2026) - "All patients tolerated maribavir treatment throughout the study period.Nineteen patients received first-line maribavir for post-HSCT CMV infection, while 20 control patients received other first-line regimens (12 predominantly foscarnet; 8 received combination therapy including ganciclovir or letermovir). In real-world, maribavir demonstrated rapid, effective, and safe clearance of CMV viremia in HSCT recipients. The retrospective cohort study demonstrates comparable CMV clearance rates between first-line maribavir and conventional antiviral regimens in HSCT recipients."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation

INTRAVENOUS BRINCIDOFOVIR EFFECTIVELY REDUCES CMV DNAEMIA IN ANTIVIRAL EXPERIENCED IMMUNOCOMPROMISED PATIENTS: RESULTS OF A PHASE 2A CLINICAL TRIAL (EBMT 2026) - P2 | "Brincidofovir (BCV) is a lipid conjugate of cidofovir that overcomes cidofovir's dose-limiting nephrotoxicity while enhancing antiviral activity against CMV and other double-stranded DNA viruses...Most patients (7/9 per Cohort) had failed ≥1 prior CMV antiviral (n=12 GCV or valGCV, 4 foscarnet, 4 letermovir, and 2 maribavir)... IV BCV was effective in reducing CMV DNAemia and was reasonably well tolerated in this population of pre-treated immunocompromised patients with CMV viremia. IV BCV is a potential treatment option for these patients with limited treatment options. These data support further study of IV BCV for treatment of CMV infections in immunocompromised patients."

Clinical • P2a data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease

CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR (EBMT 2026) - "The collected variables included: age, donor/recipient CMV serology, prophylaxis with letermovir, myeloablative or reduced-intensity conditioning, administration of serotherapy and donor type (HLA- identical sibling [MSD], haploidentical with post-transplant cyclophosphamide, other related donors [MMFD] and matched unrelated donor [MUD]. CMV reactivation is a common complication following HSCT. Letermovir could be effective for prophylaxis in seropositive paediatric patients without significant toxicity. In our series, patients who received serotherapy reactivated CMV more frequently."

Clinical • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Gastrointestinal Disorder • Pediatrics • Transplantation

CMV INFECTION AFTER ALLOGENEIC HSCT IN SERONEGATIVE RECIPIENTS TRANSPLANTED FROM A SEROPOSITIVE DONOR: A MONOCENTRIC RETROSPECTIVE STUDY (EBMT 2026) - "Since 2017, letermovir (LMV) prophylaxis is recommended after alloHSCT in R+ to decrease the incidence of clinically significant CMV infection (CS-CMVi)...First line pre-emptive treatment was given for a median of 23 days (min: 15, max: 68) and was ganciclovir in 23/24 patients (96%). Eight patients (33.3%) needed second-line foscarnet treatment due to cytopenia (n= 7) or virological failure (n= 1)... in our cohort, the incidence of positive CMV PCR in D+/R- alloHSCT patients was lower than historically reported. LMV significantly reduced the incidence of CMV PCR positivity, and was associated with a trend towards a significant reduction in the incidence of CS-CMVi, maybe due to the small size of the cohort. TBI was the only factor significantly associated with a CMV PCR positivity."

Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation

ACICLOVIR-RESISTANT HERPES SIMPLEX VIRUS IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: A CASE SERIES (EBMT 2026) - "All patients were treated with second-line antivirals (foscarnet and/or cidofovir), and three patients were treated with third-line antivirals (pritelivir). Aciclovir-resistant HSV infection in pediatric HSCT recipients is associated with high morbidity and mortality, limited therapeutic options, and significant treatment-related toxicity. Early recognition, resistance testing, timely initiation of second-line therapy and weaning of immunosuppression are critical for disease control. Emerging therapies, such as helicase-primase inhibitors and adoptive T-cell therapy, hold promise but remain limited by access and pediatric data."

Clinical • Bone Marrow Transplantation • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Herpes Simplex • Immunology • Infectious Disease • Inflammation • Keratitis • Leukemia • Myelodysplastic Syndrome • Ocular Inflammation • Ophthalmology • Pediatrics • Pneumonia • Primary Immunodeficiency • Respiratory Diseases • Sickle Cell Disease • Transplantation • Transplantation Associated Thrombotic Microangiopathy

PERSISTENT HYPONATREMIA AS A DISTINCTIVE FEATURE OF HHV-6B ENCEPHALITIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A CASE SERIES (EBMT 2026) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia during engraftment after HSCT or CRS post-CAR-T therapy could indicate HHV-6B encephalitis in children, highlighting the need for CNS evaluation for diagnosis."

Clinical • IO biomarker • Bone Marrow Transplantation • Cardiovascular • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Inflammation • Juvenile Myelomonocytic Leukemia • Movement Disorders • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • Transplantation • CD7

MANAGEMENT OF SEVERE PULMONARY COMPLICATIONS FOLLOWING HSCT IN A PATIENT WITH Β-THALASSEMIA: A CASE REPORT ON SUCCESSFUL TREATMENT OF CMV PNEUMONIA, DAH, AND BOS (EBMT 2026) - "She underwent a matched unrelated donor (9/10 HLA-matched) allo-HSCT following a myeloablative conditioning regimen (fludarabine, busulfan, cyclophosphamide, ATG). GVHD prophylaxis included tacrolimus, methotrexate, mycophenolate mofetil, and pre-emptive infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs)...The early post-transplant course was complicated by steroid-refractory, grade III acute GVHD (skin and gut), which was successfully managed with a second-line regimen of ruxolitinib, CD25 monoclonal antibody, budesonide, and additional UC-MSCs...Initial anti-CMV therapy (acyclovir/foscarnet) failed, indicating a refractory infection...Treatment with the FAM regimen (fluticasone, azithromycin, montelukast) combined with further cycles of UC-MSCs resulted in significant clinical and radiological improvement by day +220... This complex case illustrates the cascade of severe complications—refractory aGVHD, life-threatening CMV pneumonia with DAH, and..."

Case report • Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

LATE CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HSCT PERSISTS IN THE ERA OF LETERMOVIR PROPHYLAXIS – A SINGLE-CENTRE REAL WORLD STUDY (EBMT 2026) - "413/480 (86%) received reduced intensity conditioning regimens, and 397/480 were T-cell deplete (Campath 226/480; 47.1%, ATG 93/480; 19.4%, PTCy 79/480; 16.5%)...20/27 (74.1%) of the post-letermovir reactivators required treatment with an additional anti-viral agent (p=0.52); 3 required admission for treatment with foscarnet (2 having been pre-treated with valganciclovir)... CMV reactivation remains a frequent issue post-allo-HSCT. Letermovir defers the median onset of csCMV to post-D100, but does not reduce the need for further anti-viral treatment."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Pneumonia • Retinal Disorders

CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (EBMT 2026) - "Regarding GVHD prophylaxis, anti-thymocyte globulin (ATG) was used in 83.8% (n=62) of patients, and post-transplant cyclophosphamide (PTCy) was used in 17.6% (n=13). For pre-transplant antiviral prophylaxis, ganciclovir was administered to 89.2% (n=66) of patients and foscarnet to 21.6% (n=16)... In elderly haplo-HCT recipients, EBV reactivation correlates with inferior survival, whereas early CMV reactivation predicts disease relapse without compromising survival. Letermovir prophylaxis effectively mitigates CMV risk but is independently associated with increased EBV reactivation, presenting a clinical trade-off. These findings highlight the distinct prognostic implications of viral kinetics and underscore the necessity for balanced prophylactic strategies and vigilant monitoring in this vulnerable population."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

PRITELIVIR DEMONSTRATED SUPERIOR EFFICACY COMPARED TO INVESTIGATOR'S CHOICE TREATMENT FOR REFRACTORY HERPES SIMPLEX VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS: PRIOH-1, PHASE 3 SAFETY AND EFFICACY (EBMT 2026) - P3 | " In this randomized (1:1), controlled, open label trial, 101 IC patients (≥16 years) with R±R HSV mucocutaneous infection received oral pritelivir (100 mg daily; 400 mg loading dose) or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod) for up to 28 days, extendable to 42 days. Eligibility criteria included hematopoietic cell transplant, solid organ transplant, HIV, malignancy, or chronic use of immunosuppressive treatment with refractory/clinical failure (defined as no clinical improvement of lesions after ≥7 days of standard of care nucleoside analogue therapy or confirmed acyclovir resistance)... Pritelivir met the Phase 3 primary endpoint, demonstrating statistically superior efficacy compared with ICT, with a favorable safety and tolerability profile. These findings support pritelivir as a promising oral agent to address the unmet needs of refractory HSV infections in IC patients.Table 1 Incidence of TEAEs (≥ 10%): Pritelivir vs...."

Clinical • P3 data • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Primary Immunodeficiency • Solid Organ Transplantation

PROGNOSTIC IMPLICATIONS OF CMV INFECTION/DISEASE AND HHV-6 ENCEPHALITIS IN CORD BLOOD TRANSPLANT RECIPIENTS RECEIVING FOSCARNET (EBMT 2026) - "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis.Primary endpoints were the cumulative incidence of CMV infection and its impact on relapse, non-relapse mortality (NRM), and overall survival (OS)... In CBT with prophylactic FOS, CMV infection was associated with higher NRM, with CMV disease showing a more pronounced impact and adversely affecting OS. Although prophylactic FOS did not sufficiently prevent HHV-6 encephalitis, its occurrence did not affect outcomes."

Clinical • Acute Graft versus Host Disease • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases • Transplantation

REAL-WORLD USE, EFFECTIVENESS AND SAFETY OF MARIBAVIR IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CMV OR INTOLERANCE TO ANTI-CMV AGENTS: INTERIM ARISE RESULTS (EBMT 2026) - "Interim results of this European retrospective study support the real-world effectiveness and safety of maribavir in adult HCT recipients with refractory/resistant CMV or intolerance to anti-CMV agents. CMV clearance rates at maribavir discontinuation appeared to be higher than previously observed in the HCT population within the phase 3 SOLSTICE trial. The lower incidence of myelosuppression and nephrotoxicity after versus before maribavir initiation is in line with the lower hematologic and renal toxicity of maribavir compared with ganciclovir/valganciclovir and foscarnet in the overall SOLSTICE transplant population."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING IN IL2RG-MUTATED SCID AND SEVERE ACTIVE CMV INFECTION: RAPID IMMUNE RECONSTITUTION AND INFECTION CONTROL (EBMT 2026) - "Pre-transplant management included intense combined antiviral therapy with foscarnet and ganciclovir. At 6 months of age, the patient received an unmanipulated bone marrow graft from a matched sibling donor, without conditioning or serotherapy; immunosuppression was limited to cyclosporine A. Immune reconstitution and clinical outcomes were monitored longitudinally... The case supports the preference for unconditioned SCT in T−B+NK− IL2RG SCID with severe active CMV or other severe infection, especially with available matched sibling donor – an option included in recent ESID/IEWP EBMT recommendations (1). SCT without conditioning can achieve rapid T-cell reconstitution and infection control and spare the patient from dangerous organ toxicity, in the presented case also with adequate B cell reconstitution without the need for a second procedure. ReferencesLankester et al."

Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Ocular Inflammation • Ophthalmology • Primary Immunodeficiency • Retinal Disorders • Transplantation • CD4 • IL2 • IL2RG

RETROSPECTIVE REVIEW OF LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS (EBMT 2026) - "Letermovir was given as secondary prophylaxis in 2 patients—patient 1 had multiple episodes of CMV reactivations requiring extended treatment with ganciclovir or foscarnet over 3 months, while patient 4 was started on letermovir after initial PET for CMV reactivation peri-engraftment.2/14 patients developed CS-CMVi during letermovir prophylaxis. Letermovir prophylaxis appears to be safe and effective in our series of paediatric alloHSCT patients. Further research is needed to better define CMV viral load thresholds for initiating PET while on letermovir prophylaxis."

Retrospective data • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics • Transplantation

FIRST-IN-WORLD EXPERIENCE OF IMMUNOMODULATION TO PROMOTE RECIPIENT TOLERANCE TO GENE MODIFIED AUTOLOGOUS STEM CELL TRANSPLANT FOR MPS II (EBMT 2026) - P1/2 | " Three patients to date have undergone CD34+ cell collection via leukapheresis using G-CSF and plerixafor...For two patients treated following protocol amendment, gene-modified HSCs were transplanted after busulfan-based conditioning with the addition of three doses of alemtuzumab at 0.1mg/kg on day -7 to -5 during conditioning and ongoing sirolimus from day -1 with a target therapeutic range of 5 – 10 micromol/L...The patient did experience transient cytomegaloviraemia, detectable via PCR from day +6, following which they received foscarnet and ganciclovir and successfully cleared viraemia by day +24... The first patient shows early and sustained biochemical correction of nMPSII, and the second patient has undergone the conditioning regimen without concern, confirming the tolerability of our immunomodulation protocol alongside HSCGT. Further follow-up is required to correlate biochemical correction with developmental and cognitive outcomes. Treatment of a further..."

Immunomodulating • CNS Disorders • Gene Therapies • Hunter Syndrome • Immunology • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • Transplant Rejection • Transplantation • CD34 • ITGAM

FOSCARNET SODIUM ENEMA FOR REFRACTORY CMV GASTROENTERITIS AFTER HAPLOIDENTICAL HSCT: A CASE SERIES (EBMT 2026) - "Foscarnet sodium enema represents a promising, non-invasive adjunctive therapy for refractory CMV gastroenteritis after allo-HSCT. It can effectively reduce local viral burden and accelerate symptom resolution when systemic drug penetration is insufficient."

Clinical • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder

THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH ATG/PTCY-BASED GVHD PROPHYLAXIS AS PROMISING APPROACH FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER, OPEN-LABEL, PROSPECTIVE STUDY (EBMT 2026) - "GVHD prophylaxis included ATG (6 mg/kg) plus low-dose PTCy (50 mg/kg), combined with cyclosporine, mycophenolate mofetil, and a short course of methotrexate...Letermovir was used for CMV prophylaxis; CMV reactivation occurred in 7 patients and EBV reactivation in 16, all resolving with ganciclovir, foscarnet, or rituximab... These data suggest that the TBF+ATG/PTCy regimen is feasible for haplo-HSCT in ALL, with manageable transplant-related toxicity. We will further evaluate the regimen by expanding the patient cohort and extending follow-up, which are essential for efficacy and safety analysis."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Mucositis • T Acute Lymphoblastic Leukemia • Transplantation

RISK ASSESSMENT OF HERPESVIRUS REACTIVATION IN CHILDREN UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH PROPHYLACTIC USE OF LETEMOVIR: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY (EBMT 2026) - "Letermovir (LTV), a novel drug for preventing cytomegalovirus (CMV) infection, significantly reduces the need for broad-spectrum antiviral drugs such as ganciclovir and foscarnet. Prophylactic use of LTV in pediatric transplant patients can significantly reduce the risk of CMV reactivation, but these patients also experience an increased risk of HHV6 and HHV7 reactivation due to the weakened "bypass" inhibitory effect of broad-spectrum antiviral drugs, which may prolong platelet engraftment."

Observational data • Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Intravenous Brincidofovir Effectively Reduces CMV Dnaemia In Antiviral Experienced Immunocompromised Patients: Results of a Phase 2a Clinical Trial (TCT-ASTCT-CIBMTR 2026) - P2 | "Most patients (7/9 per Cohort) had failed ≥1 prior CMV antiviral (n=12 GCV or valGCV, 4 foscarnet, 4 letermovir, and 2 maribavir). IV BCV was effective in reducing CMV DNAemia and was reasonably well tolerated in this population of pre-treated immunocompromised patients. IV BCV is a potential treatment for patients with limited options. These data support further study of IV BCV for treatment of CMV infections."

Clinical • Late-breaking abstract • P2a data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease

Prevalence and Characteristics of CMV Reactivation after Chimeric Antigen Receptor T cell Therapy: A Referral Center Experience (TCT-ASTCT-CIBMTR 2026) - "Antiviral treatment was required in 28 patients, most commonly with valganciclovir, ganciclovir, or foscarnet N=17, 6, 5, respectively...Immune dysregulation, inflammatory cytokines, and T-cell dysfunction—exacerbated by steroids or anti-cytokine agents like tocilizumab or anakinra—may contribute...3. Identification of optimal timing and screening strategies for reactivation of CMV after CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Genetic Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Retinal Disorders

From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report. (PubMed, BMC Ophthalmol) - "This case illustrates CMV retinitis in the setting of JAK inhibition complicated by delayed retinal ischemia and vitreous hemorrhage arising remote from the original retinitis. Although ischemic vasculopathy is a recognized complication of CMV retinitis among non-HIV immunosuppressed patients, such sequelae have been infrequently documented in JAK inhibitor-associated cases. Ophthalmologists should maintain a high index of suspicion for CMV retinitis in this emerging population and continue close surveillance for delayed ischemic complications even after apparent disease stabilization."

Journal • Achromatopsia • Cardiovascular • Cytomegalovirus Infection • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Rheumatoid Arthritis • Rheumatology • Uveitis

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - P=N/A | N=153 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Adult T-Cell Leukemia-Lymphoma • Amyloidosis • Anemia • Aplastic Anemia • Atypical Chronic Myeloid Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Chronic Eosinophilic Leukemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Chronic Neutrophilic Leukemia • CNS Lymphoma • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Dermatology • Diffuse Large B Cell Lymphoma • Essential Thrombocythemia • Extranodal Marginal Zone Lymphoma • Eye Cancer • Follicular Lymphoma • Hairy Cell Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Hypereosinophilic Syndrome • Infectious Disease • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Mast Cell Leukemia • Multiple Myeloma • Mycosis Fungoides • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Natural Killer/T-cell Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Plasmacytoma • Polycythemia Vera • Prolymphocytic Leukemia • Sezary Syndrome • Small Lymphocytic Lymphoma • Splenic Marginal Zone Lymphoma • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • T-Cell Large Granular Lymphocyte Leukemia • Thrombocytosis • Transplantation • Waldenstrom Macroglobulinemia

Ganciclovir Pharmacokinetic Monitoring in a Pediatric Stem Cell Transplant Recipient with Human Cytomegalovirus Viremia: A Case Report (TCT-ASTCT-CIBMTR 2026) - "He failed to clear CMV with standard valganciclovir and ganciclovir pediatric dosing; resistance testing was negative... After foscarnet discontinuation, ganciclovir was continued at home...Letermovir was subsequently prescribed for secondary prophylaxis... Inadequate ganciclovir exposure may lead to treatment failure or antiviral resistance. To our knowledge , this is the first reported case of AUC -guided ganciclovir dosing in a pediatric SCT patient with CMV viremia. AUC-guided dosing is a potentially safe and effective option for pediatric patients unable to clear CMV with traditional dosing strategies ."

Case report • Clinical • PK/PD data • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatitis C • Hepatology • Immunology • Inflammation • Pediatrics • Pneumonia • Transplantation